期刊档案 · Agricultural and Biological Sciences-Animal Science and Zoology
Current Research in Pharmacology and Drug Discovery
ISSN 2590-2571 · Elsevier · Netherlands
Current Research in Pharmacology and Drug Discovery 完全开放获取，APC 约 3,280 美元，近 24 个月 41 篇文章投稿到接收中位 138 天，2025 年发文 35 篇，Scopus 收录。
研究范围
研究范围与定位
Current Research in Pharmacology and Drug Discovery 由 Elsevier 出版。按 OpenAlex 近年发文统计，该刊主要发表 SARS-CoV-2 and COVID-19 Research、COVID-19 Clinical Research Studies、Computational Drug Discovery Methods 等主题的论文，这 3 个主题约占 24.2%。（根据 OpenAlex 主题统计与中科院分区数据生成）
Current Research in Pharmacology and Drug Discovery (CRPHAR) is a new primary research, gold open access journal from Elsevier. CRPHAR publishes original papers, reviews, graphical reviews, short communications and follow-up manuscripts resulting from research in pharmacology and drug discovery that cover aspects of drug action at the cellular, molecular, and biochemical level.Current Research in Pharmacology and Drug Discovery is a peer-reviewed gold open access (OA) journal and upon acceptance all articles are permanently and freely available. It is a companion to the highly regarded review journal Current Opinion in Pharmacology (2020 Journal Impact Factor 5.547, CiteScore 9.3) and is part of the Current Opinion and Research (CO+RE) suite of journals . All CO+RE journals leverage the Current Opinion legacy-of editorial excellence, high-impact, and global reach-to ensure they are a widely read resource that is integral to scientists' workflow.Current Research in Pharmacology and Drug Discovery topics covered include neuropharmacology (psychiatry and neurodegeneration); sensory pharmacology (ocular, auditory and pain); cardiovascular; renal; respiratory; musculoskeletal; cancer; immunopharmacology (inflammation and innate immune system function); anti-infectives; gastrointestinal; endocrine; metabolic; systems pharmacology and signalling; drug metabolism; pharmaceutics and drug delivery; pharmacogenetics; analytical toxicology; pharmacokinetics; new technologies; and translational and clinical pharmacology.Current Research in Pharmacology and Drug Discovery builds on Elsevier's reputation for excellence in scientific publishing and long-standing commitment to communicating reproducible biomedical research targeted at improving human health.Expertise - Editors and Editorial Board bring depth and breadth of expertise and experience to the journal.Speed - Submission and peer review is fast, and publication of final manuscripts is instantaneous.Discoverability - Articles get high visibility and maximum exposure on an industry-leading platform that reaches a vast global audience.Ethics in Publishing: General StatementThe Editor(s) and Publisher of this Journal believe that there are fundamental principles underlying scholarly or professional publishing. For more information, please refer to: https://www.elsevier.com/conflictsofinterest
摘自期刊官网 Aims & Scope
研究方向（LetPub）：Agricultural and Biological Sciences-Animal Science and Zoology
主编 Luigino Calzetta出版商官网
编委会国家分布：中国大陆 5 位（约 14%）；主要国家 意大利 11、美国 7、中国 5、英国 2、印度 2（共 35 位编委标注了国家） 编委会 ↗出版商官网 ·
主要研究主题 OpenAlex 近年发文统计，占比为近似值
- SARS-CoV-2 and COVID-19 ResearchMedicine8.4%
- COVID-19 Clinical Research StudiesMedicine7.9%
- Computational Drug Discovery MethodsComputer Science7.9%
- Pharmacogenetics and Drug MetabolismPharmacology, Toxicology and Pharmaceutics6.5%
- Inflammatory Bowel DiseaseBiochemistry, Genetics and Molecular Biology5.1%
- Asthma and respiratory diseasesMedicine4.2%
- Nanoparticle-Based Drug DeliveryMaterials Science4.2%
- Alzheimer's disease research and treatmentsMedicine4.2%
分区与收录
学科分区与数据库收录
中科院期刊分区表
期刊分区表（ 2025年3月升级版）未收录
该期刊未被此版本分区表收录。
《新锐期刊分区表》（ 2026年3月发布）未收录
该期刊未被此版本分区表收录。
期刊分区表（ 2023年12月旧的升级版）未收录
该期刊未被此版本分区表收录。
CiteScore 分区（Scopus，2026 年 6 月版）
| 学科 | 分区 | 排名 | 百分位 |
|---|---|---|---|
| Animal Science and Zoology | Q1 | 8/520 | 98% |
| Ecology, Evolution, Behavior and Systematics | Q1 | 24/736 | 96% |
Scopus 按 CiteScore 在每个学科内为期刊排名，百分位 75 及以上为 Q1，每 25 为一档；与中科院分区是不同体系。LetPub
数据库收录
ScopusDOAJLetPub
国际期刊预警名单：各版本均未列入LetPub
不同版本、大类与小类分别展示，不将不同评价口径合并为一个分区值；投稿与考核前请确认所在机构采用的版本。
指标
影响力指标与发文规模
影响力指标
- 影响因子（出版商公布） 2020
- 5.55出版商官网 ·
- CiteScore 2026-06
- 11.4LetPub ·
- CiteScore（出版商公布）
- 11.4出版商官网 ·
- SJR 2026-06
- 1.39LetPub ·
- SNIP 2026-06
- 1.7LetPub ·
- h-index
- 34OpenAlex ·
- i10-index
- 117OpenAlex ·
- 两年平均被引
- 6.94OpenAlex ·
- Gold OA 文章占比
- 0%LetPub ·
逐年发文量 OpenAlex 统计 · 累计 247 篇 · 当年数据不完整
| 年份 | 发文量 | 其中 OA | 被引 |
|---|---|---|---|
| 2026 | 11 | 11 | 1,058 |
| 2025 | 35 | 35 | 1,150 |
| 2024 | 33 | 33 | 924 |
| 2023 | 16 | 16 | 715 |
| 2022 | 71 | 71 | 456 |
| 2021 | 66 | 66 | 77 |
不同来源的统计口径与观测时间不同，页面保留各来源原值；“出版商公布”为期刊官网自述数据。
审稿与录用
审稿周期与录用情况
文章统计的审稿周期 PubMed 登记的稿件日期 · 至
138 天投稿到接收中位数 · P25–P75 85 天 – 164 天
- 接收到上线
- 中位数 3 天（41 篇）
- 投稿到上线
- 中位数 141 天
- 样本
- 41 篇有投稿与接收日期的文章（窗口内共 43 篇），最近一篇接收于
只统计最终被录用并发表的文章，不含被拒稿件的处理时间，因此通常长于出版商公布的"首次决定时间"。
其他来源
- 平均审稿速度（社区反馈）
- 10 WeeksLetPub ·
- 投稿到首次决定
- 12 天出版商官网 ·
- 外审后首次决定
- 59 天出版商官网 ·
- 投稿到接收
- 113 天出版商官网 ·
- 接收到发表
- 3 天出版商官网 ·
- 投稿到发表（期刊自报）
- 约 18 周DOAJ ·
- 评审方式
- 单盲同行评审DOAJ
社区反馈来自投稿者样本，置信度 0.5，不代表期刊承诺；“出版商公布”的时间节点定义以官网为准。
费用与开放获取
版面费与开放获取政策
完全开放获取DOAJ
所有文章开放获取，通常向作者收取文章处理费（APC）。
| 来源 | 文章处理费 | 费用减免 | 许可证 | 观测时间 |
|---|---|---|---|---|
| DOAJ | USD 3,280 | 有 | CC BY、CC BY-NC、CC BY-NC-ND | |
| OpenAlex | USD 2,680 / EUR 2,510 / GBP 2,150 / JPY 332,400 | — | — | |
| LetPub | USD 2,500 | 有 | — | |
| 出版商官网 | USD 3,680 | — | — |
- APC 费用说明 ↗DOAJ
- 费用减免政策 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
费用以期刊官网为准；不同来源的观测时间可能不同，页面保留各来源原值，不做平均。
投稿要求
文章类型与投稿政策（官网）
投稿准备要点6 项，摘自作者指南
- 摘要
- ≤ 250 词
- 关键词
- 1–7 个
- 参考文献格式
- 顺序编码制（按引用顺序编号）
- 首次投稿格式
- 允许不按期刊格式排版（free format）
- Highlights（研究亮点）
- 必须提供
- 图文摘要
- 必须提供
接收的文章类型9 种
- graphical reviewsThe Journal publishes Research Papers, Short Communications and Graphical Reviews.未说明篇幅
- hypothesisThe Journal publishes Research Papers, Short Communications and Graphical Reviews. We support the "Your Paper Your Way" Elsevier guideline which allows authors …未说明篇幅
- meta-analysisThe Journal publishes Research Papers, Short Communications and Graphical Reviews. We support the "Your Paper Your Way" Elsevier guideline which allows authors …未说明篇幅
- research paperThe Journal publishes Research Papers, Short Communications and Graphical Reviews. We support the "Your Paper Your Way" Elsevier guideline which allows authors …未说明篇幅
- research papersThe Journal publishes Research Papers, Short Communications and Graphical Reviews.未说明篇幅
- reviewThe Journal publishes Research Papers, Short Communications and Graphical Reviews. We support the "Your Paper Your Way" Elsevier guideline which allows authors …未说明篇幅
- review articleReview Article Before submitting a review, you are encouraged to present a pre-submission proposal to the Editorial office (crphar-me@elsevier.com) for approval…未说明篇幅
- short communicationThe Journal publishes Research Papers, Short Communications and Graphical Reviews. We support the "Your Paper Your Way" Elsevier guideline which allows authors …未说明篇幅
- short communicationsThe Journal publishes Research Papers, Short Communications and Graphical Reviews.未说明篇幅
官网政策摘录AI 使用、作者资格、利益冲突、出版伦理、许可与版权、开放获取、同行评审、预印本
- AI 使用 Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
原文 ↗出版商官网 ·- 作者资格 Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
原文 ↗出版商官网 ·- 利益冲突 Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
原文 ↗出版商官网 ·- 出版伦理
Follow Elsevier's Publishing Ethics Policy 模型摘要
Authors must follow ethical guidelines stated in Elsevier's Publishing Ethics Policy.
原文 ↗出版商官网 ·- 许可与版权 License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
原文 ↗出版商官网 ·- 开放获取 Open access
We refer you to our open access information page to learn about open access options for this journal.
原文 ↗出版商官网 ·- 同行评审 Peer review
Single anonymized review process 模型摘要
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
原文 ↗出版商官网 ·- 预印本 Preprints
Preprint sharing allowed, does not count as prior publication 模型摘要
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication. In support of Open Science, this journal offers its authors a free preprint posting service on SSRN, Elsevier’s preprint and early research …
原文 ↗出版商官网 ·
摘录来自期刊官网页面，仅保留原文片段；“模型摘要”由 Workers AI 生成并经原文校验，以官网为准。
基本信息
出版信息与官方入口
- 出版商
- Elsevier
- 出版国家或地区
- Netherlands
- 出版语言
- English
- ISSN
- 2590-2571
- 官方链接
- 期刊主页 ↗DOAJ
- 投稿系统 ↗出版商官网
- 作者指南 ↗DOAJ
- Aims & Scope ↗DOAJ
- 专刊 / 特刊征稿 ↗出版商官网
- APC 费用说明 ↗DOAJ
- 费用减免政策 ↗DOAJ
- 开放获取声明 ↗DOAJ
- 许可与版权 ↗DOAJ
- 评审流程 ↗DOAJ
- 编委会 ↗DOAJ
- 查重政策 ↗DOAJ
常见问题
关于 Current Research in Pharmacology and Drug Discovery 的常见问题
Current Research in Pharmacology and Drug Discovery 的审稿周期多长？
按 2024年10月至2026年10月（近 24 个月）41 篇已发表文章登记的日期，投稿到接收的中位数为 138 天（四分位 85–164 天）；投稿社区反馈的平均审稿速度为约 10 周。文章统计只含被录用的稿件，出版商数据口径以官网为准，社区反馈来自投稿者样本，均不代表期刊承诺。
Current Research in Pharmacology and Drug Discovery 的投稿格式要求是什么？
据期刊作者指南：摘要：≤ 250 词；关键词：1–7 个；参考文献格式：顺序编码制（按引用顺序编号）；首次投稿格式：允许不按期刊格式排版（free format）；Highlights：必须提供；图文摘要：必须提供。以上由模型从作者指南提取并逐项与原文核对，投稿前请以官网最新版本为准。
Current Research in Pharmacology and Drug Discovery 的编委会里有中国学者吗？
期刊官网编委会页面上标注了国家的 35 位编委中，中国大陆 5 位（约 14%）；人数最多的国家是 意大利（11 位）、美国（7 位）、中国（5 位）。统计按编委会页面列出的机构国家计，仅供参考。
Current Research in Pharmacology and Drug Discovery 被哪些数据库收录？
据 LetPub 与 DOAJ 记录，Current Research in Pharmacology and Drug Discovery 被 Scopus、DOAJ 收录。
Current Research in Pharmacology and Drug Discovery 是开放获取期刊吗？版面费多少？
Current Research in Pharmacology and Drug Discovery 为完全开放获取。APC 约 3,280 美元。
来源与更新
本页事实来自 LetPub、出版商官网、OpenAlex、DOAJ；每个数字旁标注来源与观测日期，冲突数据保留各来源原值。LetPub 原始详情页：查看 ↗（2026-08-26 归档）。最近更新：。